Summit Therapeutics (SMMT) Interest & Investment Income (2017 - 2023)
Summit Therapeutics' (SMMT) quarterly Interest & Investment Income came in at $968000.0 in Q1 2023, up 75414.97% on a QoQ basis from $1281.9 in Q1 2020.
Summit Therapeutics (SMMT) Interest & Investment Income (2017 - 2023) Analysis & Trends
Summit Therapeutics (SMMT) has 5 years of Interest & Investment Income data on file, last reported at $968000.0 in Q1 2023.
- Quarterly Interest & Investment Income changed N/A year-over-year to $968000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was -$2.6 million (up 27.05% YoY) and the FY2019 annual result came in at $5142.9, changed N/A from the prior year.
- Interest & Investment Income climbed to $968000.0 in Q1 2023, from $1281.9 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $968000.0 in Q1 2023 to a low of -$3.6 million in Q4 2019.
- A 3-year average of -$520752.7 and a median of $1281.9 in 2020 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 50.77% in 2020, down 50.77% in 2020.
- Tracing SMMT's Interest & Investment Income over 3 years: stood at -$3.6 million in 2019, then surged by 100.04% to $1281.9 in 2020, then surged by 75414.97% to $968000.0 in 2023.
- The last three Interest & Investment Income figures came in at $968000.0 (Q1 2023), $1281.9 (Q1 2020), and -$3.6 million (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 968,000.00 |
| Mar 31, 2020 | 1,281.87 |
| Dec 31, 2019 | -3.58 Mn |
| Oct 31, 2019 | 1,237.69 |
| Mar 31, 2019 | 2,603.75 |
| Jul 31, 2018 | 3.71 Mn |
| Apr 30, 2018 | 1,401.71 |
| Jan 31, 2018 | 12,129.01 |
| Oct 31, 2017 | 4.06 Mn |
| Jul 31, 2017 | 1,290.36 |
| Apr 30, 2017 | 1,248.18 |